Epidemiology of gastrointestinal stromal tumours: Single-institution experience and clinical presentation over three decades

Sandvik, Oddvar; Søreide, Kjetil; Kvaløy, Jan Terje; Gudlaugsson, Einar; Søreide, Jon Arne

doi:10.1016/j.canep.2011.03.002

Cited by 46 publications

(31 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies report no gender differences, although a case series in Norway of 52 patients with GIST between 1980 and 2009 reported a female predominance (62% female vs. 38% male). 5 A national registry from 122 sites throughout the United States included 882 patients with GIST and reported that 78% of patients were Caucasian, 15% African American, 3% Asian and 3% Hispanic. 6 The majority (63%) of GIST are found based on patients' symptoms, although about a third can be found incidentally during abdominal imaging, endoscopy or surgery.…”

Section: Epidemiologymentioning

confidence: 99%

Review article: the biology, diagnosis and management of gastrointestinal stromal tumours

Iorio

Sawaya

Friedenberg

2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARY BackgroundGastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract with an increasing incidence. AimsTo review the biology, diagnosis and treatment of gastrointestinal stromal tumours. MethodsA PubMed search using the phrases 'Gastrointestinal stromal tumor', 'imatinib', 'c-kit'. ResultsThe diagnosis of GIST is established by histology supplemented by the immunohistochemical marker CD117, which is positive in 95% of cases. The most common site of the tumour is the stomach. Most GIST are benign with 20-30% malignant. Five-year survival for malignant GIST ranges between 35% and 65% and depends primarily on tumour size, mitotic index and location. The malignant behaviour of GIST is best assessed by invasion of adjacent structures and distant metastases. The gold standard for treatment is surgical resection. Imatinib, a tyrosine kinase inhibitor, is the primary therapy for unresectable, recurrent or metastatic disease. ConclusionsGastrointestinal stromal tumours are rare tumours of the gastrointestinal tract and they vary in presentation. When surgical resection is not achievable, imatinib is the treatment of choice.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Review article: the biology, diagnosis and management of gastrointestinal stromal tumours

Iorio

Sawaya

Friedenberg

2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Goettsch et al described an incidence rate of 2.1/million in 1995 and 12.7/million in 2003 [18]. The Norweigan study demonstrated a rate increase from 1.8 per million per million to 12.5 per million comparing 1980-1984 data to 2000-2004 [8]. A further trend for increasing GIST recognition has been noted in the latter years of other population based incidence studies [13].…”

Section: Discussionmentioning

confidence: 93%

“…A large Norweigan study from 1980 to 2009 showed an overall rate of 6.5 per million, though this rose from 1.8 per million to 12.5 per million over a 20 year period [8]. Other studies using a variety of methodologies report varying incidence rates, ranging from 0.68/100 000 in the US [8] to 2/100 000 [9] in Europe and 2.11 in China [10]. In a study similar to ours the incidence in Iceland was 1.1/100000 [11].…”

Section: Introductionmentioning

confidence: 99%

A Retrospective Study of the Incidence of GIST in Scotland from 1995 to 1999

Js¹,

Nowicki²,

G³

et al. 2014

J Clin Exp Pathol

View full text Add to dashboard Cite

show abstract

“…In recent years, the incidences of GIST have been on the rise [22–24]. The comprehensive treatment based on surgery has become a routine treatment method [11, 25–29].…”

Section: Discussionmentioning

confidence: 99%

Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor

Hao

Guo

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Background & AimsA significant benefit of imatinib adjuvant therapy for patients with high risk gastrointestinal stromal tumors (GIST) has been confirmed. However, the effect of imatinib adjuvant therapy for intermediate-risk GIST has not been well studied. In this article, we compare differences of recurrence-free survival (RFS) rates between patients with intermediate-risk GIST who accepted imatinib adjuvant therapy and those who did not.MethodA retrospective study of intermediate-risk GIST was conducted in the First Affiliated Hospital of Zhengzhou University, China. The pathology reports of 112 patients who had been treated by surgery showed intermediate-risk GIST. The treatment and control groups were designed according to the administration of imatinib adjuvant therapy (≥1 year). Survival and recurrence data were collected and RFS of each group was calculated.ResultsEighty fivepatients with intermediate-risk GIST were followed up. Thirty of them (treatment group) accepted imatinib adjuvant therapy over 1 year. Through comparing the RFS of the two groups, we established that there was no statistically significant difference in RFS rates (P=0.940).ConclusionThere is no significant benefit for patients with intermediate-risk GIST to accept imatinib adjuvant treatment.

show abstract

Epidemiology of gastrointestinal stromal tumours: Single-institution experience and clinical presentation over three decades

Cited by 46 publications

References 35 publications

Review article: the biology, diagnosis and management of gastrointestinal stromal tumours

Review article: the biology, diagnosis and management of gastrointestinal stromal tumours

A Retrospective Study of the Incidence of GIST in Scotland from 1995 to 1999

Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor

Contact Info

Product

Resources

About